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The present study was undertaken to determine oxidative/nitrosative stress in aqueous humor of alloxan-induced hyperglycemic
rabbits and to investigate the eﬀects of two oral antidiabetic drugs, pioglitazone from peroxisome proliferator-activated receptor
gamma (PPARγ) agonists and repaglinide from nonsulfonylurea KATP channel blockers. Ascorbic acid (AA), glutathione (GSH),
total antioxidant status (TAS), lipid peroxidation products (LPO), total nitrites (NO2), advanced oxidized protein products
(AOPP), and protein carbonyl groups (PCG) were determined using respective colorimetric and ELISA methods. In our
hyperglycemic animals, AA decreased by 77%, GSH by 45%, and TAS by 66% as compared to control animals. Simultaneously,
LPO increased by 78%, PCG by 60%, AOPP by 84%, and NO2 by 70%. In pioglitazone-treated animals, AA and TAS increased
above control values while GSH and PCG were normalized. In turn, LPO was reduced by 54%, AOPP by 84%, and NO2
by 24%, in relation to hyperglycemic rabbits. With repaglinide, AA and TAS were normalized, GSH increased by 20%, while
LPO decreased by 45%. Our results show that pioglitazone and repaglinide diﬀer signiﬁcantly in their ability to ameliorate
the parameters like NO2, PCG, and AOPP. In this area, the multimodal action of pioglitazone as PPARγ agonist is probably
essential.
1.Introduction
The eye is a unique organ since it is constantly exposed
to radiation, atmospheric oxygen, environmental chemicals,
and physical abrasion. In consequence, the eye provides a
unique situation for generation of reactive oxygen species
(ROS). In particular, oxidative stress is implicated in the
etiology of many ocular diseases such as glaucoma, retinal
degeneration, ocular inﬂammation, cataracts, and diabetic
complications [1–3]. Also nitrogen reactive species (RNS)
playanimportantroleindiﬀerentoxidativealterations[4,5].
Nitric oxide (NO) is an important messenger in vascular and
nervous systems or in immunological reactions including
these in the eye. On the other hand, NO formed in excess
by inducible NO synthase (iNOS) may cause serious ocular
injuries [6].
Ocular tissues and ﬂuids contain antioxidants that play
a key role in protecting them against these oxidative/nitro-
sative damages. Aqueous and vitreous humors as well as lens
contain high amounts of ascorbic acid (AA). It is generally
accepted that it oﬀers signiﬁcant protection for the eye by
suppressing generation of free radicals [7]. Also ocular glu-
tathione (GSH) participates in neutralization of reactive
species and maintains other antioxidants in their active
forms.Unfortunately,theseantioxidantsarenotabletoelim-
inate free radicals completely and if oxidative stress is severe,
it may cause cell damage or death [3].
Proteincarbonylsgroups(PCG),markersofearlyprotein
oxidation, and advanced oxidized protein products (AOPP)
have been recently described as closely related to diﬀerent
pathological situations [8–10]. Some ﬁndings also suggest2 Experimental Diabetes Research
that the changes in proteins may be important in develop-
ment of ocular diabetic complications [11].
Therefore, the present study was undertaken to deter-
mine several markers of oxidative/nitrosative stress in aque-
ous humor of alloxan-induced hyperglycemic rabbits where
such experiments have not been performed previously.
We wanted to explore potent relationship between some
commonly studied parameters of oxidative alterations: AA,
GSH, total antioxidant status (TAS), lipid peroxidation
products (LPO), total nitrites (NO2), and two markers of
oxidative protein modiﬁcation, PCG and AOPP, and search
for this which showed more expressive correlations.
It is known that structures through which aqueous
humor leaves the anterior chamber may be a target of phar-
macological manipulations. Thus, reducing ROS/RNS over-
production and its consequences may be an eﬀective strat-
egy for protection against severe ocular injuries [11, 12].
Therefore, the second goal of the present study was to in-
vestigate which of two oral antidiabetic drugs, a peroxi-
some proliferator-activated receptor gamma (PPARγ)a g o -
nist pioglitazone or a nonsulfonylurea KATP channel blocker
repaglinide could be more eﬀective in ameliorating these
oxidative/nitrosative changes.Pioglitazone belonging chemi-
callyto 2,4-thiazolidinediones family(TZDs)actsin diabetes
mainly by decreasing insulin resistance at the level of the
muscle and liver. It has been shown to be potent antioxidant
in diﬀerent pathological situations connected with oxidative/
nitrosative stress including diabetes [13, 14]. Repaglinide,
from nonsulfonylurea KATP channel blockers, is a carbamoyl
methylbenzoicacidderivativewiththeeﬀectonearlyinsulin
secretion and reducing postprandial glucose directly [15].
Additionally,someresultsfromtheliteraturehavepreviously
demonstrated that it may have positive eﬀects on parameters
of oxidative/nitrosative stress [16, 17].
2.MaterialandMethods
2.1. Animals and Chemicals. White male New Zealand
rabbits (the mean weight 3.1kg) were housed in a controlled
environment with 12h light and dark cycles. They were
provided with standard diet and water ad libitum. Animal
care was in accordance with the “Principles of Laboratory
AnimalCare”(NIHpublicationNo.86-23,revised1985)and
with the Guidelines of Medical University of Lublin Animal
Ethics Committee. The rabbits were divided into six groups
of 5 animals: normal control (Group C), control treated with
pioglitazone (Group CP), control treated with repaglinide
(Group CR), hyperglycemic (Group H), hyperglycemic
treated with pioglitazone (Group HP), and hyperglycemic
treated with repaglinide (Group HR). Hyperglycemia was
induced by a single intravenous injection of 80mg/kg of
alloxan. Two weeks after the injection when hyperglycemia
was veriﬁed by blood glucose concentration higher than
11mmol/L, administration of pioglitazone at a dose of
1mg/kg and repaglinide at a dose of 0.3mg/kg was started
and continued for 4 weeks (the start of experiment). The
drugs were given directly to oral cavity using a syringe
without a needle, every day before the morning feeding.
During experiment, glucose concentration was monitored
once a week. At the end of experiment, the animals were
sacriﬁced with pentobarbital sodium at a dose of 60mg/kg.
The aqueous humor was collected by a 26-G needle attached
to a tuberculin syringe with special care to avoid blood
contamination. The needle was introduced into anterior
chamber and ca. 100μL aqueous humor was withdrawn. The
samples were stored at −70◦C until analysis.
TASwasassessedusingacommerciallyavailabletestfrom
RandoxLaboratoriesLtd.(UK)whileAAestimationwasper-
formed according to Kyaw [18]. GSH and LPO were deter-
mined using Bioxytech GSH-400 and LPO-586 kits from
OxisResearch(USA).ThestablemetabolitesofNOwereesti-
mated using a Nitrate/Nitrite Assay Kit from Fluka Chemi-
cals (UK). Nitrates were reduced to nitrites by incubation of
each sample for 120min in the presence of nitrate reductase
and NADPH. Then, total nitrites were assayed by adding
of Griess reagent and measuring the absorbance at 540nm.
PCG and AOPP levels were determined using respective
ELISA or colorimetric kits from Immundiagnostik AG
(Germany). Protein content was determined by the method
of Lowry et al. [19] using bovine serum albumin as standard.
Two spectrophotometers, UV-Vis CE-6000 from CECIL
Instruments (UK) and a Microplate Reader PowerWave XS
from Bio-Tek Instruments Inc. (USA), were used.
2.2. Statistical Analysis. All numerical data are presented as
the mean with respective standard error (SEM). The sig-
niﬁcance of diﬀerences was determined with Kruskal-Wallis
and Mann-Whitney’s U tests. Multiple regression and Spear-
man’s rank coeﬃcients were used to investigate the possible
correlations between AOPP or PCG level and other parame-
ters. Probability P less than 0.05 were considered signiﬁcant.
For all statistical evaluation, statistica software was used.
3. Results
In hyperglycemic animals, there were decreases of AA by
77%, GSH by 45%, and TAS by 66% as compared to control
animals. Simultaneously, there were increases of LPO by
78%, PCG by 60%, AOPP by 84%, and NO2 by 70%.
Pioglitazone increased AA and TAS above control values
and normalized GSH and PCG. In turn, LPO was reduced
by 54%, AOPP by 84% and NO2 by 24% in relation to
hyperglycemic rabbits. With repaglinide treatment, AA and
TAS were normalized while GSH increased by 20% and
LPO decreased by 45% in relation to hyperglycemic rabbits.
However, repaglinide did not aﬀect the levels of PCG, AOPP,
and NO2 (Table 1).
Multiple regression analysis did not show signiﬁcant cor-
relations. However, some correlations were observed when
respective pairs of parameters were taken into account. In
hyperglycemic group, we observed a negative correlation
between AOPP and GSH, and positive correlations in pairs
AOPP-LPO and AOPP-NO2 (Figures 1(a)–1(c)). In hyper-
glycemic pioglitazone-treated group, similar correlations
wereobservedbetweenAOPPandLPO,andAOPPandNO2.
In the case of PCG, correlations for both hyperglycemicExperimental Diabetes Research 3
Table 1: Eﬀects of pioglitazone and repaglinide on oxidative/nitrosative stress parameters in the aqueous humor of control and hyperglyce-
mic rabbits.
Group C Group CP Group CR Group H Group HP Group HR
TAS (mmol/mL) 1.99 ±0.10 1.96 ±0.15 1.90 ±0.15 0.67 ± 0.09a 2.37 ± 0.14a,b 1.56 ± 0.15b
AA (μg/mL) 12.90 ±1.05 13.94 ±0.93 10.03 ±1.05 3.02 ± 0.38a 21.87 ± 1.18a,b 12.62 ± 1.36b
GSH (nmol/mL) 138.7 ±4.49 144.2 ±12.84 117.7 ± 3.32a 76.14 ± 6.56a 131.4 ± 5.86b 91.06 ± 8.17a,b
NO2 (nmol/mL) 39.04 ±2.84 43.67 ±4.09 37.44 ±2.5 113.4 ± 7.63a 102.0 ± 8.78a 142.5 ± 2.54a
LPO (nmol/mL) 0.57 ±0.27 0.89 ±0.25 0.68 ±0.023 2.64 ± 0.14a 1.21 ± 0.11a,b 1.45 ± 0.17a,b
PCG (nmol/mg protein) 17.86 ±1.36 16.98 ±1.30 24.13 ± 1.63a 44.49 ± 2.15a 20.46 ± 2.96b 40.46 ± 3.57a
AOPP (nmol/mg protein) 2.53 ±0.26 2.44 ±0.26 2.76 ±0.32 16.15 ± 2.24a 4.31 ± 0.18a,b 19.29 ± 0.88a,b
Values are mean ± SEM (n = 5). TAS: total antioxidant status, AA: ascorbic acid, GSH: glutathione, NO2: total nitrites, PCG: protein carbonyls, AOPP:
advanced oxidized protein products. C: control rabbits, CP: control rabbits treated with pioglitazone, CR: control rabbits treated with repaglinide, H:
hyperglycemic rabbits, HP: hyperglycemic rabbits treated with pioglitazone, HR: hyperglycemic rabbits treated with repaglinide. aSigniﬁcant at P<0.05
versus Group C. bSigniﬁcant at P<0.05 versus Group H.
and hyperglycemic pioglitazone-treated animals were also
signiﬁcant, although respective r values were lower than
these for AOPP (Figures 1(d) and 1(e)). Because repaglinide
did not aﬀect the altered protein oxidation, in this case
respective correlations were not calculated.
4. Discussion
In the eye of diabetic subjects, the occurrence of oxidative
stress was demonstrated as depletion of GSH, an important
aqueous antioxidant [20]. Between others, GSH maintains
the second major antioxidant AA in its active form [21].
Relation between these two antioxidants was conﬁrmed in
the present study where diminished levels of GSH and AA
were stated in aqueous humor of our hyperglycemic animals.
Some reports suggest that intracellular GSH level may be
decreased by RNS derived from NO produced in excess by
iNOS. As a consequence, production of nitrosoglutathione
and formation of protein-mixed disulﬁdes with glutathione
have been reported [22]. Previously, excessive levels of NO
were stated in vitreous ﬂuid of patients with proliferative
diabetic retinopathy [6]. It was also observed in the present
study together with a decreased level of GSH. The altered
antioxidant balance in aqueous humor of our hyperglycemic
rabbits was additionally conﬁrmed by a signiﬁcant increase
in lipid peroxidation. Previously, elevated concentrations of
LPO were stated in vitreous ﬂuid of diabetic db/db mice [23]
and in aqueous ﬂuid of glaucoma patients [20].
Under situation of oxidative stress, many attention is
devoted to oxidative damages in proteins [24]. They may
result, between others, from formation of diﬀerent protein
adducts. Early modiﬁcations often bring carbonyl groups to
proteinsandmaybeestimatedas2,4-dinitrophenylhydrazine
derivativesorPCG[25].Recently,alargeinterestliesonlatter
products of protein oxidation (AOPP) which are deﬁned as
dityrosine-containingcross-linkedproteinproducts[10,26].
In aqueous humor of our hyperglycemic animals, the both
markers, PCG and AOPP, were elevated in comparison with
respective controls. Previously, similar changes were found
in plasma of type 2 diabetic patients where higher increase
in the level of AOPP compared with PCG was found. It
was explained by lower susceptibility of AOPP cross-linked
proteins to proteolysis and their subsequent accumulation in
plasma [10]. In the present study, we additionally concluded
that AOPP correlated better than PCG to other examined
parameters (Figure 1).
In our study AA, TAS, GSH, and LPO were ameliorated
by the two drugs, pioglitazone and repaglinide. However,
onlyafterpioglitazone,signiﬁcantchangesinNO2,PCG,and
AOPP were observed. It is known that AOPP are formed
by action of chloraminated oxidants, mainly hypochlorous
acid and chloramines, produced by myeloperoxidase (MPO)
[26, 27]. On the other hand, it has been showed that piogli-
tazone inhibits proinﬂammatory factors including MPO.
Therefore, its present eﬀect on AOPP in aqueous humor of
hyperglycemicanimalsmaybe,atleastinpart,aconsequence
of the above ability.
It is known that expression of many genes including
proinﬂammatory cytokines, adhesion molecules, and others
such as iNOS was regulated by a nuclear factor NF-κB.
It is also supposed that beneﬁcial eﬀects of antioxidants
against oxidative complications may involve eﬀective inhi-
bition of NF-κB[ 6]. Such mechanism for antioxidative and
anti-inﬂammatory properties of PPARγ agonists, including
pioglitazone, has been proposed [28–30]. Previous data
about decreased levels of NO2 and MPO after pioglitazone
in lung and testis of our hyperglycemic animals conﬁrm this
[31, 32]. However, the exact mechanism whereby the drug
exerts its antioxidant eﬀect is still unclear. In this area, the
multimodal action of PPARγ agonists is probably essential
[33].
As far as concerning KATP channel blockers, it cannot
be excluded that they may aﬀect oxidative/nitrosative stress.
After repaglinide, total serum antioxidant capacity [17]a n d
lipid peroxidation were ameliorated [15, 16]. After another
drug mitiglinide, signiﬁcant decreases of lipid peroxidation
and nitrotyrosine were also observed [34]. However, all these
eﬀects occurred in type 2 diabetes where they could be
probable by better controlling postprandial hyperglycemia
and thus by the cluster of oxidative stress. Additionally,
it has been stated that insulin per se reduces the level of
NF-κB. Because NF-κB regulates the expression of enzymes
involved in ROS/RNS generation, in this way, insulin can
modulate the mechanisms involved in oxidative/nitrosative4 Experimental Diabetes Research
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Figure 1: Correlations between GSH, LPO, and NO2 and respective protein oxidation marker, AOPP ((a)–(c)) or PCG ((d)–(f)), in
hyperglycemic (Group H) and hyperglycemic pioglitazone-treated (Group HP) animals.Experimental Diabetes Research 5
Table 2: Blood glucose and plasma insulin concentrations in control and hyperglycemic rabbits at the start and the end of experiment.
Group
Glucose (mmol/L) Insulin (mU/L)
Start End Start End
Control (C) 6.2 ±0.15 .7 ±0.31 3 .16 ±1.26 13.30 ±1.12
Control-pioglitazone (CP) 6.5 ±0.35 . 9 ± 0.3b 11.74 ±0.72 14.12 ± 0.98b
Control-repaglinide (CR) 6.3 ±0.24 . 0 ± 0.3a,b,∗ 12.83 ±1.01 20.0 ± 1.42a,b,∗
Hyperglycemic (H) 26.3 ± 2.3a 24.9 ± 2.8a 3.21 ± 0.63a 2.79 ± 0.79a
Hyperglycemic-pioglitazone (HP) 27.2 ± 0.3a 23.9 ± 1.8a 2.31 ±0.15 2.01 ± 0.34a
Hyperglycemic-repaglinide (HR) 26.4 ± 1.2a 24.0 ± 2.3a 2.32 ± 0.15a 2.02 ± 0.04a
Values are mean ± SEM (n = 5). aSigniﬁcant at P<0.05 versus Group C. bSigniﬁcant at P<0.05 versus Group H. ∗Signiﬁcant at P<0.05 versus start.
stress [35]. In our previous studies concerning heart, lung,
andtestis,repaglinidesigniﬁcantlyaﬀectednitrotyrosineand
LPO levels but did not aﬀect NO2 and PCG levels [31, 32]. It
was conﬁrmed in the present study by the lack of any eﬀect
on PCG, AOPP, and NO2.
What is important in the present study is that piogli-
tazone and repaglinide did not signiﬁcantly aﬀect glucose
concentration in our hyperglycemic animals. After alloxan
injection, these animals preserved insulin secretion but its
amount was very low because of destruction of many B cells
by alloxan. Therefore, repaglinide could not stimulate its
s e c r e t i o ni ns u ﬃcient way and pioglitazone failed to aﬀect its
sensitivity (Table 2). This lack of antihyperglycemic activity
was expected and used by us to diﬀerentiate, at least in part,
some direct antioxidative/antinitrosative eﬀects of the drugs
from eﬀects mediated via increased insulin action. When
animals with type 2 diabetes were used, these two kinds of
eﬀects could not be separated.
5. Conclusions
In aqueous humor of our hyperglycemic animals, the
decreased AA, GSH, and TAS as well as increased LPO, NO2,
PCG, and AOPP were observed conﬁrming the exposition
of ocular structures on oxidative/nitrosative stress. It was
observed that correlations between AOPP and other factors
were more expressive than the same correlations for PCG.
We concluded that AOPP which was easy to obtain, corre-
sponded better than PCG to other examined parameters. In
addition, antioxidative/antinitrosative properties of pioglita-
zone and repaglinide were compared. The results obtained in
the present study conﬁrm that pioglitazone and repaglinide
diﬀer signiﬁcantly in their ability to ameliorate the examined
markers of oxidative/nitrosative stress in aqueous humor,
especially in respect to protein modiﬁcations. It cannot be
excluded that KATP channel blockers like repaglinide may
aﬀect oxidative/nitrosative stress but PPARγ agonists like
pioglitazone seem to act more comprehensively which was
conﬁrmed independently on their action oh hyperglycemia.
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